Psoriasis

Boni E. Elewski, MD, shares her management pearls of how to treat difficult nail psoriasis and onychomycosis at the 2023 Winter Clinical Hawaii Dermatology Conference.

The year-long study gives insight to the treatment’s efficacy and safety of durability.

Patients with psoriasis were more likely to receive emergency food from churches, food banks, or soup kitchens.

Union therapeutics is also developing the drug for treatment of atopic dermatitis and hidradenitis suppurativa.

New pathways of care are needed to improve health care spending.

Patients with psoriasis seem to suffer more in the wintertime when flare-ups are much more common.

More drugs and treatment options continue to be explored, and in 2022, there were some exciting advancements in these areas for dermatologists treating psoriasis.

Click here to answer this week's poll.

A variety of topicals and biologics are now available to treat children affected by this challenging condition.

Patient enrollment is now open for the study conducted by late-stage biopharmaceutical company, Soligenix.

Arcutis Biotherapeutics' indication expansion is based on data from MUSE studies.

A biologic from Germany offers a new treatment option for a number of dermatologic conditions.

Recent review explores the difficulties of treating pediatric psoriasis.

New research examined brain structure and connectivity in patients with psoriasis.

Arcutis Biotherapeutics announced new positive data involving itch and itch-related sleep loss in adults with plaque psoriasis.

Shanna Miranti, MPAS, PA-C, shares highlights from her shared session at the 2022 SDPA Conference.

In the past, there were many efforts to develop topical MTX, but the major obstacle was its physicochemical properties.

Psoriasis has long been linked to cardiovascular disease, including coronary artery disease, myocardial infarction, and heart failure.

Dr Mark Lebwohl provides insight into the educational needs of both patients and providers surround the utilization of spesolimab and its importance in the management of patients with generalized pustular psoriasis.

Mark G. Lebwohl, MD, comments on the clinical implications of the recent approval of spesolimab for the treatment of generalized pustular psoriasis.

An expert in dermatology presents the case of a 64-year-old female with a long history of plaque psoriasis, focusing on her disease severity and age-related management considerations.

Expert dermatologists discuss the risk of candidiasis with IL-17 inhibitors when managing plaque psoriasis and how to manage candidiasis.

Drs Mark G. Lebwohl and Alice B. Gottlieb discuss the novel mechanism of bimekizumab and how it can change the treatment landscape for plaque psoriasis.

Goals of generalized pustular psoriasis treatment are reviewed by Dr Mark Lebwohl, where he comments on the need to consider patient disease severity and comorbidities.

Dr Mark Lebwohl comments on the treatment and management considerations for a patient suffering from severe generalized pustular psoriasis, highlighting the inefficiency of systemic steroids in the management of this condition.

Mark G. Lebwohl, MD, introduces the case of a 28-year-old female nurse with a long history of psoriasis, commenting on her past medical history and initial presentation.

Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss the durability of IL-17 inhibitors in managing plaque psoriasis.

Expert dermatologists discuss how to select treatment for plaque psoriasis while taking comorbidities into consideration.

Nonsteroidal topical agents and TYK2 inhibitors may join an already full armamentarium.

Drs Mark G. Lebwohl and Alice B. Gottlieb discuss how to select treatment for plaque psoriasis based on mechanism of action.